Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02933073 · ClinicalTrials.gov registry record · Phase 1
Study of Oncoimmunome for the Treatment of Stage III/IV Ovarian Carcinoma
A Phase 1 study, sponsored by UConn Health.
- Terminated
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT02933073: Clinical Trial Phase 1 study, sponsored by UConn Health.
NCT02933073 is a Phase 1 study that was terminated before completion, run by UConn Health. The registered enrollment target is 8 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02933073, a Phase 1 study, was terminated before completion, sponsored by UConn Health.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This is a Phase I trial to test the safety and feasibility of OncoImmunome vaccine in stage III/IV ovarian cancer patients. OncoImmunome is a tumor specific vaccine formulation which is predicted to elicit tumor-protective immune responses. A total of 15 patients will be enrolled from the Principal Investigator (PI) clinical practice. These patients will have just successfully completed standard of care surgical debulking with preservation of fresh tumor, chemotherapy treatment and be in documented clinical remission prior to receiving the vaccine. The patients receive 6-monthly doses of the vaccine and are monitored for up to 5 years post vaccination. This is a personalized vaccine, unique to each patient and is the "first in human" use.
Primary Outcome
Number of Participants with Oncoimmunome Immunization related Adverse Events (AE) as assessed by CTCAE v. 4.03.
Interventions
- BIOLOGICAL OncoImmunome
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2016-11 |
| Est. Completion | 2022-08 |
| Phase | Phase 1 |
Why NCT02933073 stopped before completion
NCT02933073 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 1 intervention - of which OncoImmunome is the first listed.
NCT02933073 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02933073 about?
NCT02933073 is a clinical study titled "Study of Oncoimmunome for the Treatment of Stage III/IV Ovarian Carcinoma". This is a Phase I trial to test the safety and feasibility of OncoImmunome vaccine in stage III/IV ovarian cancer patients. OncoImmunome is a tumor specific vaccine formulation which is predicted to elicit tumor-protective immune responses. A total of 15 patients will be enrolled from the Principal ...
What is the current status of trial NCT02933073?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2016-11. Estimated completion is 2022-08.
What interventions are being tested in trial NCT02933073?
The interventions under investigation include: OncoImmunome (BIOLOGICAL).
Who is sponsoring clinical trial NCT02933073?
This trial is sponsored by UConn Health, which has 178 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02933073's enrollment target sits among peer trials
8 1959th of 2000 higher than 29 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia